<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04111380</url>
  </required_header>
  <id_info>
    <org_study_id>Jianwei Zhou</org_study_id>
    <nct_id>NCT04111380</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers</brief_title>
  <official_title>Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers: a Prospective, Open Label, Single-arm Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSPC Ouyi Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To verify the role of nab-paclitaxel in second or later-line treatment in advanced biliary&#xD;
      tract cancers, the investigators designed a prospective, exploratory, single arm,single&#xD;
      center phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with&#xD;
      cisplatin as second or later-line treatment in advanced biliary tract cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate [ORR]</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival [PFS]</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival [OS]</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate [DCR]</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Biliary Tract Cancers</condition>
  <arm_group>
    <arm_group_label>Nab-paclitaxel and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin and nab-paclitaxel: Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin and nab-paclitaxel</intervention_name>
    <description>Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.</description>
    <arm_group_label>Nab-paclitaxel and Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ranges from 18 to 75 years&#xD;
&#xD;
          -  Radiographically, histologically or/and cytologically diagnosed intrahepatic&#xD;
             cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer.&#xD;
&#xD;
          -  Received at least one first-line systemic treatment for advanced or metastatic&#xD;
             diseases and failed, with imaging evidence of disease progression.&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  According to the RECIST1.1 standard, at least one measurable objective lesion should&#xD;
             be judged.&#xD;
&#xD;
          -  Expected survival more than 12 weeks&#xD;
&#xD;
          -  The laboratory test meet the following requirements:&#xD;
&#xD;
        Bone marrow function: neutrophils ≥ 1.5×10(9)/L, platelets ≥ 100×10(9)/L, hemoglobin ≥ 90&#xD;
        g/L Liver function：Total bilirubin ≤ 1.5x ULN；AST and ALT) ≤ 2.5x ULN Renal function：Cr ≤&#xD;
        1.5x ULN，Ccr ≥ 45 ml/min Coagulation function：INR≤1.5×ULN, PT≤1.5ULN, APTT within the&#xD;
        normal range&#xD;
&#xD;
          -  Not concomitant with other uncontrollable benign disease before the recruitment(e.g.&#xD;
             the infection in the kidney, lung and liver).&#xD;
&#xD;
          -  During the non-lactation period, contraceptive measures should be taken in patients of&#xD;
             child-bearing age during this trial. The test ofβ- HCG was negative.&#xD;
&#xD;
          -  The patient has good compliance with the planned treatment, understands the research&#xD;
             process of the study and signs a written informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With Chemotherapy contraindication, known to be allergic, highly sensitive or&#xD;
             intolerable to research-related drugs or excipient.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Refuse or fail to sign informed consent to participate in the trial&#xD;
&#xD;
          -  Grade 2 or above peripheral neuropathy or hemorrhage according to NCI CTCAE 4.03&#xD;
&#xD;
          -  Combined with severe cardiovascular disease, including hypertension that cannot be&#xD;
             controlled by medical treatment(BP≥160/95mmHg), unstable angina, a history of&#xD;
             myocardial infarction in the past 6 months,Congestive heart failure&gt;NYHA grade II,&#xD;
             severe arrhythmia, pericardial effusion, etc.&#xD;
&#xD;
          -  Patients with severe systemic infections or other serious diseases.&#xD;
&#xD;
          -  Combined with other primary tumors&#xD;
&#xD;
          -  Patients not suitable for the group according to the judgement of the researcher, with&#xD;
             mental disease.&#xD;
&#xD;
          -  Patients with symptomatic central nervous system (CNS) metastases who require&#xD;
             radiotherapy, surgery or sustained corticosteroid use, and untreated brain metastases&#xD;
             that cause any symptoms&#xD;
&#xD;
          -  Prior exposure to nab-paclitaxel&#xD;
&#xD;
          -  The investigator determined that unable to complete the study due to medical, social,&#xD;
             or psychological reasons or were unable to sign valid informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianwei Zhou, MD&amp;PhD</last_name>
    <phone>13298360725</phone>
    <email>drzhoujw@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology , Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianwei Zhou, MD&amp;PhD</last_name>
      <phone>13298360725</phone>
      <email>drzhoujw@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

